- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT06686394
Исследование патритумаба дерукстекана с другими противораковыми агентами у участников с HER2-положительным раком молочной железы, который распространился и не может быть удален хирургическим путем (MK-1022-009)
HERTHENA-Breast-01: Многоцентровое открытое исследование по подбору дозы фазы 1b/2 для оценки безопасности и противоопухолевой активности патритумаба дерукстекана у участников с HER2-положительным неоперабельным местнораспространенным раком молочной железы или метастатическим раком молочной железы
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Обзор исследования
Статус
Подробное описание
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Toll Free Number
- Номер телефона: 1-888-577-8839
- Электронная почта: Trialsites@msd.com
Места учебы
-
-
-
Haifa, Израиль, 3109601
- Рекрутинг
- Rambam Health Care Campus ( Site 0011)
-
Контакт:
- Study Coordinator
- Номер телефона: 04-7776234
-
Petah Tikva, Израиль, 4941492
- Рекрутинг
- Rabin Medical Center ( Site 0012)
-
Контакт:
- Study Coordinator
- Номер телефона: +972-505533121
-
Ramat Gan, Израиль, 5265601
- Рекрутинг
- Sheba Medical Center ( Site 0010)
-
Контакт:
- Study Coordinator
- Номер телефона: 03-5304498
-
-
-
-
Ontario
-
Kingston, Ontario, Канада, K7L 2V7
- Рекрутинг
- Kingston General Hospital ( Site 0061)
-
Контакт:
- Study Coordinator
- Номер телефона: 6135336541
-
Toronto, Ontario, Канада, M5G 2M9
- Рекрутинг
- Princess Margaret Cancer Centre ( Site 0001)
-
Контакт:
- Study Coordinator
- Номер телефона: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Канада, H3T 1E2
- Рекрутинг
- Jewish General Hospital ( Site 0003)
-
Контакт:
- Study Coordinator
- Номер телефона: 514-340-8222
-
Montreal, Quebec, Канада, H2X 3E4
- Рекрутинг
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Контакт:
- Study Coordinator
- Номер телефона: (514)890-8000 x20737
-
-
-
-
Camden
-
London, Camden, Соединенное Королевство, NW1 2PG
- Рекрутинг
- University College London Hospital ( Site 0041)
-
Контакт:
- Study Coordinator
- Номер телефона: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Соединенное Королевство, G12 0YN
- Рекрутинг
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Контакт:
- Study Coordinator
- Номер телефона: +441413017000
-
-
London, City of
-
London, London, City of, Соединенное Королевство, EC1A 7BE
- Рекрутинг
- St Bartholomew s Hospital ( Site 0040)
-
Контакт:
- Study Coordinator
- Номер телефона: +442073777000
-
-
-
-
Colorado
-
Aurora, Colorado, Соединенные Штаты, 80045
- Рекрутинг
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Контакт:
- Study Coordinator
- Номер телефона: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, Соединенные Штаты, 02215
- Рекрутинг
- Dana-Farber Cancer Institute ( Site 0050)
-
Контакт:
- Study Coordinator
- Номер телефона: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, Соединенные Штаты, 08901
- Рекрутинг
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Контакт:
- Study Coordinator
- Номер телефона: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, Соединенные Штаты, 29605
- Рекрутинг
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Контакт:
- Study Coordinator
- Номер телефона: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, Соединенные Штаты, 22031
- Рекрутинг
- Inova Schar Cancer Institute ( Site 0051)
-
Контакт:
- Study Coordinator
- Номер телефона: 571-472-4724
-
-
-
-
-
Seoul, Южная Корея, 03080
- Рекрутинг
- Seoul National University Hospital ( Site 0030)
-
Контакт:
- Study Coordinator
- Номер телефона: 82-2-2072-0850
-
Seoul, Южная Корея, 05505
- Рекрутинг
- Asan Medical Center ( Site 0031)
-
Контакт:
- Study Coordinator
- Номер телефона: +82-2-1688-7575
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Япония, 467-8602
- Рекрутинг
- Nagoya City University Hospital ( Site 0020)
-
Контакт:
- Study Coordinator
- Номер телефона: +81-52-851-5511
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Другие имена:
Trastuzumab administered via IV infusion
Другие имена:
Trastuzumab biosimilar administered via IV infusion
Другие имена:
|
|
Экспериментальный: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Другие имена:
Trastuzumab administered via IV infusion
Другие имена:
Trastuzumab biosimilar administered via IV infusion
Другие имена:
Pertuzumab administered via IV infusion |
|
Экспериментальный: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Другие имена:
Trastuzumab administered via IV infusion
Другие имена:
Trastuzumab biosimilar administered via IV infusion
Другие имена:
Tucatinib administered as oral tablets |
|
Экспериментальный: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Другие имена:
Trastuzumab administered via IV infusion
Другие имена:
Trastuzumab biosimilar administered via IV infusion
Другие имена:
Pertuzumab administered via IV infusion |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Временное ограничение: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Временное ограничение: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Временное ограничение: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Временное ограничение: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Временное ограничение: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Временное ограничение: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Временное ограничение: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Временное ограничение: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Временное ограничение: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Директор по исследованиям: Medical Director, Merck Sharp & Dohme LLC
Публикации и полезные ссылки
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Новообразования по локализации
- Новообразования
- Кожные заболевания
- Заболевания груди
- Заболевания кожи и соединительной ткани
- Новообразования молочной железы
- Аминокислоты, пептиды и белки
- Белки
- Антитела, моноклональные, гуманизированные
- Антитела, моноклональные
- Антитела
- Иммуноглобулины
- Иммунопротеины
- Белки крови
- Сывороточные глобулины
- Глобулины
- Трастузумаб
- пертузумаб
- Тукатиниб
- Патритумаб Деруксткан
- Огиври
- Ontruzant
Другие идентификационные номера исследования
- 1022-009
- MK-1022-009 (Другой идентификатор: MSD)
- jRCT2041250022 (Идентификатор реестра: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Идентификатор реестра: EU CT)
- U1111-1346-4321 (Идентификатор реестра: UTN)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .